Genetic Testing

Dave Amber1 reviewed the public's risks in genetic DNA testing and the potential need for federal oversight to ensure the accuracy and predictability of these tests to avoid erroneous preventive surgical and medical care. The added user cost to the public for this Food and Drug Administration surveillance is yet to be determined. DNA testing has become more complicated than expected in that the variations of genetic mutations are numerous. A negative DNA test for a known hereditary cancer syndro

Written byRamon Fusaro
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Dave Amber1 reviewed the public's risks in genetic DNA testing and the potential need for federal oversight to ensure the accuracy and predictability of these tests to avoid erroneous preventive surgical and medical care. The added user cost to the public for this Food and Drug Administration surveillance is yet to be determined. DNA testing has become more complicated than expected in that the variations of genetic mutations are numerous. A negative DNA test for a known hereditary cancer syndrome does not always indicate an absence of that syndrome as the kindred may have a previously unrecognized mutation. If a hereditary cancer syndrome has been identified in a kindred and DNA testing of its members is requested, multiple members of the kindred will need to be tested for the establishment of the presence of that mutation. It is only then that a negative DNA test in other members of the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies